Thursday 5 January 2023 – 2.08 pm
DUBAI, 5th January, 2020 (WAM) — The UAE tops the list of a group of countries in the Middle East and Africa in terms of the number of innovative medicines that contain a new active substance and in the speed of study and approval of the dossier regulations for medicines.
This achievement reflects the Ministry of Health and Prevention’s strategy to strengthen the country’s leadership and competitiveness in the healthcare and pharmaceutical fields, as part of the “We Are the Emirates 2031” vision, which constitutes a new vision and development plan national action through which the UAE will complete its development journey over the next decade and approximately the next 50 years.
The Ministry worked to increase its efficiency in this field by reducing the study period of regulatory dossiers for innovative medicines, as 187 products with new active substances were approved during the study period.
This study, conducted by IQVIA, a healthcare systems company, focused on comparing the standard for registration and delivery of innovative medicines that contain a new active ingredient, which includes market approval data for medicines in the period from 2018 to the first quarter of 2021.
His Excellency Dr. Amin Hussein Al-Amiri, Assistant Under-Secretary for the Health Regulatory Sector, confirmed that this achievement is a testament to the steadfast commitment of the wise government to ensure the safety and efficacy of medicines available to members of society, as the state invested in building an effective healthcare system with international regulatory standards, which has helped streamline the process of bringing new drugs to market. The time it takes to get approval for drug regulatory files has helped attract many pharmaceutical companies in the UAE.
He added that the drug regulatory dossier approval process in the country is thorough, comprehensive and effective, as modern technologies are used to ensure that applications are reviewed and decisions are made in a timely manner.
He praised the fruitful and constructive collaboration it provides to local and international pharmaceutical companies in the country, within the framework of the strategic partnership established by the Ministry with these companies, which is reflected in the development of the pharmaceutical sector in the country and in improving the quality of life of patients.
Al Amiri said this achievement enhances the UAE’s position as a leading center for healthcare and medicines in the region and a regional and international platform for pharmaceutical companies looking to launch their products in the Middle East, underlining the enthusiasm to expedite drug registration procedures, provide health care to patients, and provide support to the pharmaceutical industry.
Emad Al-Ali / Halima Al-Shamsi
